Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
HELIUM, USP is an inhaled gas product approved by the FDA in October 2019 for inhalation use. The product is a medical gas with no specified pharmacologic mechanism of action or indication in available labeling. It is currently in peak lifecycle stage as a specialty inhalation therapy.
Product is at peak commercial stage with moderate competitive pressure (30%), indicating stable market presence and potential for established commercial team support.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
C2 Esophageal Squamous Epithelium Dysplasia
Worked on HELIUM, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
HELIUM, USP currently shows zero linked job openings, indicating either a stable, fully-staffed team or limited growth in hiring. Working on this peak-stage specialty gas product offers opportunity to support an established commercial franchise, though expansion roles may be limited.